GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese
patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing
schedule.